Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurdle.
David Hardy, a leading market and innovation strategist at Thermo Fisher Scientific with 25 years of experience at the intersection of data, automation, and laboratory science, is helping organizations bridge the gap between data chaos and actionable insight.
Topics discussed:
David Hardy’s early experiences managing NMR data at AstraZeneca and the origins of his interest in data management (03:46)
Lessons from retail analytics and returning to scientific data challenges (05:21)
Identifying the persistent problem of data connectivity in labs, despite growing data volumes and new technologies (06:40)
The most common pushbacks to digital solutions: long-term commitment and culture change (07:38)
What mindsets and leadership approaches support successful digital transformation (08:43)
Recognizing fragmentation and spotting “hidden” data silos in biotech labs (10:06)
Where data fragmentation hurts the most—especially for cross-disciplinary questions and CMC reporting (11:06)
Build vs. buy: deciding whether to create in-house digital tools or work with external vendors (13:50)
The importance of adaptable systems and preparing for inevitable change in biotech data management (14:43)
Smart insight: True digital transformation is not a project, but a process—a way of working that requires vision, patience, and continual adaptation. The labs that break down data silos and connect their digital resources are better positioned to unlock the full promise of biotech: faster discoveries, more robust compliance, and therapies delivered to patients without unnecessary delay.
The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.
Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
Episodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio
Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
Connect with David Hardy
LinkedIn: www.linkedin.com/in/david-hardy-46331823
Thermo Fisher Scientific website: www.thermofisher.com
Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.
Support the show

Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in today’s market and production realities.
Key topics discussed
Why asking if a novel host will "replace CHO" is the wrong question for scientists and manufacturers (00:11)
Critical dimensions to evaluate: cost structure, speed, and intrinsic product quality (01:20)
Review of five alternative platforms with current clinical and regulatory status: Plant farming for speed and decentralization (03:42)
Insect cells for VLPs and complex proteins (05:00)
Cell-free protein synthesis for ADCs and unique conjugation requirements (06:23)
Moss for monoclonal antibodies with distinct glycosylation patterns (07:50)
Filamentous fungi for high secretion and thermotolerance (08:47)

A practical host selection framework by molecule type and manufacturing context (09:59)
Detailed constraints and advantages of each platform, including cost, infrastructure, timeline, and product attributes (10:09)
Analysis of silkworm production as a disruptive possibility for future biologics manufacturing (13:09)
The evolving toolkit available to bioprocess scientists—and why "CHO replacement" is a distraction from more relevant questions (12:06)
Smart insight:
The real development over the past decade is that bioprocess scientists now have a credible, validated toolkit of alternatives for specific molecules in specific contexts. The practical implication: know this landscape well enough to ask the right host selection question at program initiation, before you've built months of process development around a platform you chose by default.
Here are the episodes referenced:
Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran
Next:
If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.
Support the show

In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous data analysis, David examines where established and emerging hosts find their strengths—and their limits—in today’s biomanufacturing environment.
Topics Discussed
The historical dominance of CHO cells and what’s changed in the last decade (00:08)
Three critical areas where alternative hosts might outperform CHO: cost, speed, and intrinsic product quality (04:52)
Moss as a production platform: regulatory advantages, glycosylation, and oncology antibodies (05:47)
Microalgae’s carbon-negative potential and the current 1000-fold yield challenge (08:28)
Molecular farming (plant-based production): timelines, case of the Medicago COVID-19 vaccine, and overcoming political—not technical—barriers (10:41)
Silkworm-based production: infrastructure cost, individual variability, and progress in vaccines (13:07)
Cyanobacteria: promise of photosynthetic biomanufacturing and current limitations for clinical use (15:06)
The pattern emerging among all alternative platforms: finding niche advantages rather than universally replacing CHO (18:25)
A framework for evaluating novel hosts moving forward (19:14)
Part 2 examines whether “Will it replace CHO?” is the right question to be asking at all, and introduces an alternative framework for evaluating the issue more effectively.
Smart insight:
None of the “novel hosts” are universal CHO replacements. Winners emerge in narrow niches: plant farming for pandemic-scale vaccines, silkworms in veterinary and oral applications, and cyanobacteria as a long-term bet for sustainable production.
Here are the episodes referenced:
Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran
Next:
If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.
Support the show

Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and startup hurdles higher than most founders realize.
Michael Rome, Managing Director at Foresite Capital, joined the Smart Biotech Scientist Podcast to dissect what’s really driving funding decisions today, and what early-stage founders must do to stand out.
Key topics discussed:
The financial cycle of biotech investment before, during, and after the COVID-19 boom (02:47)
Why investors are now focused on clear pathways to approved drugs and how founders should frame their proposals (06:10)
The evolving importance of CMC expertise and manufacturing readiness for startups at different stages (07:44)
Leadership traits and execution qualities investors appreciate in biotech founders and teams (09:18)
Promising scientific and market areas including small molecule oncology, degraders, and heterobifunctional molecules (11:24)
Practical advice for founders preparing for fundraising: focusing on unmet medical needs and market analysis (14:55)
The impact of recent M&A activity and regulatory challenges at the FDA on the future of biotech investment (16:27)
The importance of open communication and collaboration between scientists and investors (18:47)
Smart insight: For those preparing their next fundraising push, Michael advised:
Start with the end in mind: Outline the unmet need, the clinical and market pathway, and the product vision first
Reverse engineer your innovation: Work backwards from market and regulatory needs to inform your technical approach, not the other way around.
Frame your business case: Make it obvious to investors how your solution advances value in the ecosystem
If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:
Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
Connect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.com
Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.
Support the show

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.
Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both scientist and investor. Having trained as a Caltech biochemist and incubated dozens of biotech companies, he’s seen first-hand how world-class discoveries become market-ready solutions—or get left behind.
Topics discussed:
Why strong science isn't always enough to secure funding (00:25)
Insights on diverse biotech investing strategies, time horizons, and mandate differences between venture firms (02:44)
The advantage of Foresite’s multi-stage and cross-sector investment model (03:32)
Michael’s journey from science and math enthusiast to biotech investor (04:49)
The importance of founding team track records and repeat entrepreneurs in early-stage company building (12:53)
The evolving global landscape: company formation, investment, and biotech innovation in Asia (with a focus on China) (15:56)
Effects of shifting geopolitical and regulatory landscapes on US, European, and Asian biotech partnerships (20:25)
The practicalities and tradeoffs of outsourcing drug development, R&D, and manufacturing overseas (22:04)
Smart insight: Engage with investor perspectives early: align your work to real market needs. Seek partnerships with industry leaders and proven entrepreneurs, embrace global resources, networks, and collaborations to maximize both scientific and commercial potential.
If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:
Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
Connect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.com
Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.
Support the show